Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Neogenomics Q3 2026 Results: Net Loss of $7.55M, Loss Narrows

NeoGenomics reported a net revenue increase to $209.3 million for the third quarter of 2026, up from $187.8 million in the prior year. The company significantly reduced its quarterly net loss to $7.5 million compared to $27.1 million in 2025, driven by improved gross margins and lower general and administrative expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue209.3187.8
Gross profit96.680.4
Profit before tax-8.0-26.4
Net income-7.5-27.1

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+11.4%
Gross margin46.2%
Operating margin-3.8%
Source

10-Q filed with the SEC, NASDAQ: NEO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Neogenomics Inc: key numbers

Share price
$15.41Close, Nov 16
Market cap
$1.99B
Shares outstanding
129.39MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Testing LaboratoriesSIC 8734

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Neogenomics Inc

All →
4:07 PM ET 8-K
Financial Results

Neogenomics Financial Results

NeoGenomics reported third-quarter 2026 revenue of $209 million, an 11% year-over-year increase driven by 29% growth in Next-Generation Sequencing (NGS) revenue. The company significantly improved its bottom line, reducing its GAAP net loss to $8 million from $27 million in the prior year, and raised its full-year 2026 revenue and adjusted EBITDA guidance.

“Our third-quarter results reinforce that we have the right strategy in place and the right team to execute against it. Clinical revenue growth of 13% continues to showcase the strength of our broad-based testing solutions portfolio, with NGS revenue growing a strong 29% and NGS test volume growing 17%.”

Tony Zook, Chief Executive Officer of NeoGenomics
4:09 PM ET 8-K
Leadership Change

Neogenomics Leadership Change

NeoGenomics announced a planned leadership succession where current President and COO Warren Stone will succeed Tony Zook as CEO and join the Board, effective January 4, 2027. Tony Zook will transition to the role of Executive Chairman, while current Board Chair Lynn Tetrault will step down as Chair and not stand for re-election at the 2027 Annual Meeting.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.